A 68-year-old retired schoolteacher from Kundapura is found to be in atrial fibrillation at a routine visit. She has hypertension and diabetes, and her creatinine clearance is 48 mL/min. She takes diclofenac most days for her knees. The echocardiogram shows no mitral stenosis. Two days later, in the same OPD, a 45-year-old man with rheumatic heart disease and moderate mitral stenosis is also in AF. The intern wants to start apixaban for both. These are illustrative cases, not real patients.
By the end of this article you will know why one of them must not have it, and how the tool scores the other.
Use this at the bedside
Open the tool: AF Anticoagulation Pathway
Get the CDSS app: install the MEDiscuss CDSS on your phone
1. Valvular AF: The Branch That Is Not Rare Here
Patients with AF and moderate-to-severe mitral stenosis, or a mechanical heart valve, have “valvular AF”. NOACs (apixaban, rivaroxaban, dabigatran) are strictly contraindicated in them, because they fail to prevent valve thrombosis and stroke. They need a vitamin K antagonist, warfarin or acenocoumarol (Acitrom), with INR monitoring. The ICMR Standard Treatment Workflow, revised January 2026, puts it in one line: a vitamin K antagonist only for severe mitral stenosis or a metallic valve, and a direct oral anticoagulant otherwise.
“How often will I meet this?” More often than the European guidelines suggest. The tool used to say:
- In India, Rheumatic Heart Disease (RHD) remains highly prevalent, though the incidence is reducing, so this branch is not a rare one here.
So the man with mitral stenosis gets warfarin, not apixaban. The intern’s mistake is an easy one: the word “non-valvular” sits in every NOAC trial, and it is easy to forget that it is the first question, not a footnote.
2. Scoring the Stroke Risk: The Sex Point
The tool computes CHA₂DS₂-VASc, which remains the instrument in widest use in Indian practice and the one the ICMR workflow scores. Female sex is a risk modifier, not an independent risk factor. In the absence of other factors, a woman scores 1, but this does not confer significant stroke risk, and oral anticoagulation (OAC) is not recommended on that basis alone. Three current documents handle the point differently:
| Source | Position |
|---|---|
| 2024 ESC atrial fibrillation guideline | Replaces CHA₂DS₂-VASc with CHA₂DS₂-VA, removing sex from the score entirely. A woman with no other risk factor now scores 0 rather than 1 |
| 2023 ACC/AHA guideline | Retains CHA₂DS₂-VASc as one of several validated instruments and recommends anticoagulation on the magnitude of annual risk, roughly 2% or more per year, rather than on any single score |
| ICMR Standard Treatment Workflow, revised January 2026 | Prints the score with no sex-category row and anticoagulates above 1 |
So read the sex point off the score, not into it. The tool anticoagulates above 1 once the sex point is read off. Our schoolteacher scores hypertension 1, diabetes 1, age 65 to 74 1 and female sex 1: a total of 4. Without the sex point it is 3, well above 1. She needs anticoagulation.
3. Why Her Kidneys Do Not Add Stroke Points
Until 19 October 2026, ticking the renal box in the tool added 2 points for a creatinine clearance below 60 mL/min (R₂CHA₂DS₂-VASc). It no longer does: the box now gives a dosing and bleeding caution only. “Why the change? Surely bad kidneys raise the stroke risk?” Here are the two reasons the tool used to give:
- What the derivation actually was. The 2 points are from R₂CHADS₂ (Piccini 2013), which added renal function to CHADS₂, not to CHA₂DS₂-VASc, and improved net reclassification by 6.2 per cent against CHA₂DS₂-VASc and by 8.2 per cent against CHADS₂. It was derived in ROCKET AF and validated in ATRIA, and ROCKET AF enrolled only patients with a CHADS₂ of 2 or more and a creatinine clearance of 30 or more. So the renal points were established in patients who were already at moderate to high risk. A patient whose only risk factor is a clearance below 60 was not in that cohort.
- The contrary evidence. Roldan and colleagues asked whether chronic kidney disease adds predictive information to CHADS₂ and CHA₂DS₂-VASc. In an anticoagulated outpatient cohort it did not. Renal function predicts a poor overall prognosis, but the risk factors already in the two scores carry the information.
Neither the 2024 ESC guideline nor the 2023 ACC/AHA guideline scores renal function in the stroke risk assessment, and neither does the tool. Her clearance of 48 still matters, but for the dose, not for the decision.
4. The Bleeding Score Is Not a Veto
A high HAS-BLED score (3 or more) should never be used on its own to deny a patient anticoagulation when the stroke risk is high. It flags the need for closer monitoring, and for correcting the bleeding risks that can be changed: optimising the blood pressure, stopping NSAIDs, reducing alcohol. Her daily diclofenac is exactly such a risk. It stops; the anticoagulant starts.
5. Which Drug, and What Dose
- NOACs are recommended as first-line therapy over warfarin in eligible, non-valvular patients, because of a significantly lower risk of intracranial haemorrhage and no need for routine INR monitoring.
- Renal dosing: all NOACs need dose reduction in severe renal impairment. Dabigatran is heavily renally cleared and should be avoided in severe CKD; apixaban is the preferred choice in advanced kidney disease.
The decision, in the tool’s own words, involves shared decision-making, considering the patient’s values, the absolute stroke risk and the absolute bleeding risk.
Back to Our Patients
The man with moderate mitral stenosis has valvular AF: warfarin with INR monitoring, never a NOAC. The schoolteacher has non-valvular AF with a score of 4 (3 without the sex point): a NOAC, dosed for her clearance of 48, with her diclofenac stopped and her blood pressure controlled. Her kidneys changed her dose, not her stroke score.
Try This
A 58-year-old woman with paroxysmal AF has no hypertension, diabetes, heart failure, vascular disease or past stroke. What is her CHA₂DS₂-VASc, and does she need anticoagulation? Illustrative case.
Answer. Her score is 1, from female sex alone. Read the sex point off: she has no other risk factor, and the tool, like the 2024 ESC position, does not recommend anticoagulation on that basis. On the ESC’s CHA₂DS₂-VA she scores 0. Score her again at 65, or when a risk factor appears.
Take-Home Points
- Ask about mitral stenosis and mechanical valves first: in valvular AF a NOAC is contraindicated.
- Read the sex point off CHA₂DS₂-VASc: female sex alone is not a reason to anticoagulate.
- Renal function changes the dose of the anticoagulant, not the stroke score.
- A high HAS-BLED score is a reason to correct bleeding risks, not to withhold anticoagulation.
- In advanced kidney disease, apixaban is preferred and dabigatran avoided.
For the patient’s side of this conversation, see Doctor, I Was Told To Have Atrial Fibrillation; for warfarin, Warfarin Dosage Adjustment: A Practical Approach; for the stroke this is all about, Acute Stroke and the NIH Stroke Scale: The Evidence Behind the Pathway.
Use this at the bedside
Open the tool: AF Anticoagulation Pathway
Get the CDSS app: install the MEDiscuss CDSS on your phone
Declaration: the author built and maintains the tool. It is free to use. The figures in this article are those the tool carried in its Evidence tab on 5 November 2026, each from the source the tool names. The illustrative cases follow the tool’s rules; check the tool’s result for a real patient.
References
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the EACTS. Eur Heart J. 2024;45(36):3314-3414.
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1-e156.
- Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare. Standard Treatment Workflow: Atrial Fibrillation (ICD-11 BC81.31). Revised January 2026.
- Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-272.
- Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510.
- Roldan V, Marin F, Manzano-Fernandez S, et al. Does chronic kidney disease improve the predictive value of the CHADS₂ and CHA₂DS₂-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost. 2013;109(5):956-960.
- Pisters R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding… Chest. 2010.
- Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R₂CHADS₂ index in the ROCKET AF and ATRIA study cohorts. Circulation. 2013;127(2):224-232.
- Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498. [Superseded by the 2024 ESC guideline; retained as the source of the CHA₂DS₂-VASc thresholds this engine computes]
